Zevra Therapeutics (ZVRA) Exchange Rate Effect (2022 - 2026)
Zevra Therapeutics' (ZVRA) quarterly Exchange Rate Effect came in at $233000.0 in Q1 2026, up 162.63% YoY from $88716.5 in Q1 2025, and up 172.36% on a QoQ basis from -$322000.0 in Q4 2025.
Zevra Therapeutics (ZVRA) Exchange Rate Effect (2022 - 2026) Analysis & Trends
Zevra Therapeutics (ZVRA) has 5 years of Exchange Rate Effect data on file, last reported at $233000.0 in Q1 2026.
- Quarterly Exchange Rate Effect rose 162.63% year-over-year to $233000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $633000.0 (up 398.43% YoY) and the FY2025 annual result came in at $28000.0, down 93.83% from the prior year.
- Exchange Rate Effect climbed to $233000.0 in Q1 2026, from -$322000.0 in the prior quarter.
- In the past five years, Exchange Rate Effect ranged from a high of $671000.0 in Q4 2024 to a low of -$491000.0 in Q3 2024.
- A 5-year average of $64200.0 and a median of $64000.0 in 2025 frame the typical range for Exchange Rate Effect.
- Annual changes were most pronounced in 2023 — Exchange Rate Effect sank 780.0% — and 2024, when it jumped 219.03%.
- Tracing ZVRA's Exchange Rate Effect over 5 years: stood at $189000.0 in 2022, then jumped by 84.66% to $349000.0 in 2023, then jumped by 92.26% to $671000.0 in 2024, then plunged by 147.99% to -$322000.0 in 2025, then jumped by 172.36% to $233000.0 in 2026.
- The last three Exchange Rate Effect figures came in at $233000.0 (Q1 2026), -$322000.0 (Q4 2025), and $64000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -3.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -300,000.00 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.84 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -14,590.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -2.45 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -287,000.00 |
| 10 | Zevra Therapeutics | 671.75 Mn | 450.18 Mn | 38.18 Mn | -342,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -342,000.00 |
| Jun 30, 2026 | -342,000.00 |
| Mar 31, 2026 | 233,000.00 |
| Mar 31, 2026 | 233,000.00 |
| Dec 31, 2025 | -322,000.00 |
| Dec 31, 2025 | -322,000.00 |
| Sep 30, 2025 | 64,000.00 |
| Sep 30, 2025 | 64,000.00 |
| Jun 30, 2025 | 658,000.00 |
| Jun 30, 2025 | 658,000.00 |
| Mar 31, 2025 | -372,000.00 |
| Mar 31, 2025 | -372,000.00 |
| Dec 31, 2024 | 671,000.00 |
| Dec 31, 2024 | 671,000.00 |
| Sep 30, 2024 | -491,000.00 |
| Sep 30, 2024 | -491,000.00 |
| Jun 30, 2024 | 319,000.00 |
| Jun 30, 2024 | 319,000.00 |
| Mar 31, 2024 | -45,000.00 |
| Mar 31, 2024 | -45,000.00 |